{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:16:44Z","timestamp":1788333404708,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study aimed to examine sex-disaggregated adverse event signals associated with growth impairment in pediatric patients, utilizing data from the FDA adverse event reporting system, with a particular focus on growth hormone and related therapeutic agents. A disproportionality analysis was performed on FDA adverse event reporting system data spanning 2004 Q1 to 2025 Q1. The analysis encompassed 3281 growth impairment-related reports, disaggregated by gender, employing Reporting Odds Ratios (ROR) and proportional reporting ratios for signal detection, with temporal patterns assessed via Weibull distribution modeling. Significant sex-disaggregated disparities in safety signals were identified. Somatropin exhibited a stronger association with growth impairment in females (ROR 76.85, 95% CI 65.52\u201390.15) than in males (ROR 37.31, 95% CI 32.99\u201342.20). Deflazacort showed a male-exclusive signal (ROR 58.25, 95% CI 41.27\u201382.21), while imatinib displayed a higher risk in females (ROR 15.55, 95% CI 11.29\u201321.42) compared to males (ROR 4.17, 95% CI 2.91\u20135.99). Temporal analysis revealed an early-failure pattern, with 50.6% of events occurring within 180 days. These findings generate the hypothesis that sex-disaggregated pharmacovigilance in pediatrics, particularly for growth-modulating therapies, may reveal differential reporting patterns. Should these signals be validated in controlled prospective studies, they could inform the development of customized monitoring frameworks and dosing strategies aimed at potentially mitigating risks in hypothesized high-risk subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049802","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:02:06Z","timestamp":1784322126000},"page":"e49802","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analysis of sex-stratified adverse event signals in growth impairment: Insights from the FDA adverse event reporting system"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9659-123X","authenticated-orcid":false,"given":"Xu","family":"Junyu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Huzhou Normal University, First People\u2019s Hospital, Huzhou, Zhejiang, China"},{"name":"School of Medicine, Huzhou Normal University, Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Huzhou Normal University, First People\u2019s Hospital, Huzhou, Zhejiang, China"},{"name":"School of Medicine, Huzhou Normal University, Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jingnan","sequence":"additional","affiliation":[{"name":"School of Medicine, Huzhou Normal University, Huzhou, Zhejiang, China"},{"name":"Department of Radiology, The First Affiliated Hospital of Huzhou Normal University, First People\u2019s Hospital, Huzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Luying","sequence":"additional","affiliation":[{"name":"School of Medicine, Huzhou Normal University, Huzhou, Zhejiang, China"},{"name":"Department of Radiology, The First Affiliated Hospital of Huzhou Normal University, First People\u2019s Hospital, Huzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Huzhou Normal University, First People\u2019s Hospital, Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Huzhou Normal University, First People\u2019s Hospital, Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"792877","DOI":"10.3389\/fphar.2021.792877","article-title":"Potential adverse events reported with the janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews.","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"e14862","DOI":"10.1111\/cns.14862","article-title":"Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4\/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system.","volume":"30","author":"Xiao","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4168\/aair.2024.16.6.567","article-title":"Can vaccinations trigger or exacerbate chronic urticaria?","volume":"16","author":"Ye","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40360-025-00861-y","article-title":"The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database.","volume":"26","author":"Hu","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"20543581231221891","DOI":"10.1177\/20543581231221891","article-title":"High-throughput computing to automate population-based studies to detect the 30-day risk of adverse outcomes after new outpatient medication use in older adults with chronic kidney disease: a clinical research protocol.","volume":"11","author":"Abdullah","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/ph17030342","article-title":"Safety of dual orexin receptor antagonist daridorexant: a disproportionality analysis of publicly available FAERS data.","volume":"17","author":"Cicala","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"1433472","DOI":"10.3389\/fped.2024.1433472","article-title":"Defining clavicle growth in infancy using chest radiographs.","volume":"12","author":"Hadamek","year":"2024","journal-title":"Front Pediatr"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MED.0b013e32834ed61f","article-title":"Inflammatory cytokines and growth in childhood.","volume":"19","author":"Marcovecchio","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13023-022-02372-z","article-title":"Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study.","volume":"17","author":"Savarirayan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"3","DOI":"10.6065\/apem.2346206.103","article-title":"An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database).","volume":"29","author":"Geffner","year":"2024","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"e00541","DOI":"10.1002\/prp2.541","article-title":"Individualized medicine: sex, hormones, genetics, and adverse drug reactions.","volume":"7","author":"Moyer","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"935627","DOI":"10.3389\/fphar.2022.935627","article-title":"Signal detection of pediatric drug-induced coagulopathy using routine electronic health records.","volume":"13","author":"Nie","year":"2022","journal-title":"Front Pharmacol"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"1376535","DOI":"10.3389\/fphar.2024.1376535","article-title":"Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R15-20260902","first-page":"14","article-title":"Similar biological medicinal products containing recombinant human growth hormone: european regulation.","volume":"69","author":"Pavlovic","year":"2008","journal-title":"Horm Res"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s10728-020-00390-1","article-title":"A disability bioethics reading of the FDA and EMA evaluations on the marketing authorisation of growth hormone for idiopathic short stature children.","volume":"28","author":"Murano","year":"2020","journal-title":"Health Care Anal"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14740338.2024.2396645","article-title":"A real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting system.","volume":"24","author":"Lin","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1109\/T-C.1972.223570","article-title":"Techniques ror change detection.","volume":"C-21","author":"Lillestrand","year":"1972","journal-title":"IEEE Trans Comput"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"673068","DOI":"10.3389\/fimmu.2021.673068","article-title":"Gender may influence the immunosuppressive actions of prednisone in young patients with inflammatory bowel disease.","volume":"12","author":"Lucaf\u00f2","year":"2021","journal-title":"Front Immunol"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"1521358","DOI":"10.3389\/fphar.2025.1521358","article-title":"Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database.","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"e206826","DOI":"10.1001\/jamapediatrics.2020.6826","article-title":"Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates: a systematic review and network meta-analysis.","volume":"175","author":"Ramaswamy","year":"2021","journal-title":"JAMA Pediatr"},{"key":"R22-20260902","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40264-015-0265-0","article-title":"Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems.","volume":"38","author":"Osokogu","year":"2015","journal-title":"Drug Saf"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3390\/medicina60071156","article-title":"Anti-TNF alpha and risk of lymphoma in rheumatoid arthritis: a systematic review and meta-analysis.","volume":"60","author":"Imam","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"469","DOI":"10.5114\/ceji.2020.103422","article-title":"Chronic inflammation and the growth hormone\/insulin-like growth factor-1 axis.","volume":"45","author":"Witkowska-S\u0119dek","year":"2020","journal-title":"Cent Eur J Immunol"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"15899","DOI":"10.1038\/s41598-020-72946-z","article-title":"Differential epigenetic regulation between the alternative promoters, PRDM1\u03b1 and PRDM1\u03b2, of the tumour suppressor gene PRDM1 in human multiple myeloma cells.","volume":"10","author":"Romero-Garc\u00eda","year":"2020","journal-title":"Sci Rep"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/10253890.2015.1053451","article-title":"Neuroimmune mechanisms of stress: sex differences, developmental plasticity, and implications for pharmacotherapy of stress-related disease.","volume":"18","author":"Deak","year":"2015","journal-title":"Stress"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"746924","DOI":"10.3389\/fendo.2021.746924","article-title":"Sex dimorphic responses of the hypothalamus-pituitary-thyroid axis to energy demands and stress.","volume":"12","author":"Parra-Montes de Oca","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R28-20260902","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12889-023-15110-2","article-title":"A decade of child pedestrian safety in England: a bayesian spatio-temporal analysis.","volume":"23","author":"Shoari","year":"2023","journal-title":"BMC Public Health"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11102-018-0884-4","article-title":"How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.","volume":"21","author":"Van Esdonk","year":"2018","journal-title":"Pituitary"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamapediatrics.2024.4463","article-title":"Guiding child health policy with science: the JAMA pediatrics health and the 2024 US election theme.","volume":"178","author":"Galbraith","year":"2024","journal-title":"JAMA Pediatr"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"100996","DOI":"10.1016\/j.arr.2019.100996","article-title":"The influence of vitamin D supplementation on IGF-1 levels in humans: a systematic review and meta-analysis.","volume":"57","author":"Kord-Varkaneh","year":"2020","journal-title":"Ageing Res Rev"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6065\/apem.2448258.129","article-title":"Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations.","volume":"30","author":"Maniatis","year":"2025","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R33-20260902","doi-asserted-by":"crossref","first-page":"e20259904","DOI":"10.1590\/s1677-5538.ibju.2025.9904","article-title":"Management of adverse effects in testosterone replacement therapy.","volume":"51","author":"Basheer","year":"2025","journal-title":"Int Braz J Urol"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatr Neurol"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"4802172","DOI":"10.1155\/2018\/4802172","article-title":"Implication of topical steroids in the onset of osteoporosis.","volume":"2018","author":"Milyani","year":"2018","journal-title":"Case Rep Pediatr"},{"key":"R36-20260902","doi-asserted-by":"crossref","first-page":"113180","DOI":"10.1016\/j.celrep.2023.113180","article-title":"Effector memory T cells induce innate inflammation by triggering DNA damage and a non-canonical STING pathway in dendritic cells.","volume":"42","author":"Meibers","year":"2023","journal-title":"Cell Rep"},{"key":"R37-20260902","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.2174\/1570159X20666220119125040","article-title":"Targeting PI3K by natural products: a potential therapeutic strategy for attention-deficit hyperactivity disorder.","volume":"20","author":"Noori","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"R38-20260902","doi-asserted-by":"crossref","first-page":"1451045","DOI":"10.3389\/fonc.2024.1451045","article-title":"The role of short-chain fatty acid metabolism in the pathogenesis, diagnosis and treatment of cancer.","volume":"14","author":"Hou","year":"2024","journal-title":"Front Oncol"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"662535","DOI":"10.3389\/fphar.2021.662535","article-title":"Transport of drugs and endogenous compounds mediated by human OCT1: studies in single- and double-transfected cell models.","volume":"12","author":"Haberkorn","year":"2021","journal-title":"Front Pharmacol"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00204-020-02706-5","article-title":"Long noncoding RNA LINC00844-mediated molecular network regulates expression of drug metabolizing enzymes and nuclear receptors in human liver cells.","volume":"94","author":"Li","year":"2020","journal-title":"Arch Toxicol"},{"key":"R41-20260902","doi-asserted-by":"crossref","first-page":"19160216241278659","DOI":"10.1177\/19160216241278659","article-title":"Canadian real-world study long-term clinical results using dupilumab for chronic rhinosinusitis with polyps.","volume":"53","author":"Kilty","year":"2024","journal-title":"J Otolaryngol Head Neck Surg"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:00:19Z","timestamp":1788332419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":41,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049802","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2025-09-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}